

**Amendments to the Claims and Listing of the Claims:**

Please cancel claims 13, 15 and 36, without prejudice, and amend claims 4, 7, 12, 16 and 37, without prejudice, as set forth in the following listing of the claims, which replaces all prior listings of the claims:

1. - 3. (Cancelled)

4. (Currently Amended) The composition according to claim 37, comprising wherein component (a) is a salt of zolpidem selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts.

5. (Previously Presented) The composition according to claim 4, wherein the salt is the tartrate salt.

6. - 11. (Cancelled)

7. (Currently Amended) The composition according to claim 37, comprising from 24 to 80 mg/ml of wherein the zolpidem (expressed as the free base) is present in a concentration of from 24 to 80 mg/ml.

8. - 11. Cancelled)

12. (Currently Amended) The composition according to claim 37, comprising 50 to 700 mg/ml wherein the SBE-CD is present in a concentration of 100 to 400 mg/ml.

13. – 15. (Cancelled)

16. (Currently Amended) The composition according to claim 37, wherein the composition is an aqueous solution and comprises consists essentially of from 30 to 60 mg/ml of zolpidem tartrate, 100 to 300 mg/ml SBE-CD and 2 to 10 mg/ml of chitosan glutamate.

17. - 31. (Cancelled)

32. (Withdrawn-Previously Presented) A method of administering zolpidem or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method comprises the intranasal administration of a composition as defined in claim 37.

33. (Withdrawn-Previously Presented) A method of treating or preventing insomnia, which method comprises the intranasal administration of a composition as defined in claim 37.

34. (Withdrawn-Previously Presented) A method of treating a neurological disorder or Parkinson's disease, which method comprises the intranasal administration of a composition as defined in claim 37.

35. (Withdrawn-Previously Presented) A method according to claim 34, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.

36. (Cancelled)

37. (Currently Amended) A composition in the form of an aqueous solution for nasal delivery of zolpidem or a pharmaceutically acceptable salt thereof, wherein the composition ~~comprises~~ consists essentially of:

- (a) 16 to 97 mg/ml of zolpidem (expressed as the free base);
- (b) 50 to 400 mg/ml of sulfobutylether β-cyclodextrin (SBE-CD); and
- (c) 1 to 2 mg/ml of chitosan, a salt, or a derivative thereof formed by bonding acyl and/or alkyl groups with the hydroxyl groups, but not the amino groups of chitosan or a salt of the derivative thereof; and

wherein the composition has a pH of 3.5 to 5.6 and a viscosity of less than 150 cp.